## Article

# Performance of VIDAS<sup>®</sup> Diagnostic Tests for the Automated Detection of Dengue Virus NS1 Antigen and of Anti-Dengue Virus IgM and IgG Antibodies: a Multicentre, International Study

Alice F. Versiani <sup>1,‡,‡</sup>, Antoinette Kaboré <sup>2,‡</sup>, Ludovic Brossault<sup>3</sup>, Loïc Dromenq<sup>3</sup>, Thayza M.I.L. dos Santos <sup>1</sup>, Bruno H.G.A. Milhim <sup>1</sup>, Cássia F. Estofolete <sup>1</sup>, Assana Cissé <sup>4</sup>, Abel C. Sorgho <sup>5</sup>, Florence Senot <sup>3</sup>, Marie Tessonneau <sup>3,\*</sup>, Serge Diagbouga <sup>4,†</sup> and Mauricio L. Nogueira <sup>1,†</sup>

- <sup>1</sup> Departamento de Doenças Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, SP, Brazil; afversiani@gmail.com (A.F.V.); Thayza@gmail.com (T.M.I.L.S.); brunohgam@hotmail.com (B.H.G.A.M.); cassiafestofolete@gmail.com (C.F.E.); mauricio.nogueira@edu.famerp.br (M.L.N.)
- <sup>2</sup> Institut de Recherche en Sciences de la Santé (IRSS), Centre MURAZ, Ouagadougou, Burkina Faso; aswkabore@yahoo.fr
- <sup>3</sup> BioMérieux SA, 69280 Marcy-l'Étoile, France; ludovic.brossault@biomerieux.com (L.B.); loic.dromenq@biomerieux.com (L.D.); florence.senot@biomerieux.com (F.S.)
- <sup>4</sup> Institut de Recherche en Sciences de la Santé (IRSS), Ouagadougou, Burkina Faso; assanacisse@yahoo.fr (A.C.); diagbouga.serge@gmail.com (S.D.)
- <sup>5</sup> Institut de Recherche en Sciences de la Santé (IRSS), Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso; abelcyriac.sorgho@yahoo.fr
- \* Current affiliation: Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA
- \* Correspondence: marie.tessonneau@biomerieux.com; Tel.: +33-4-7887-3630
- ‡ These authors contributed equally to this work
- <sup>+</sup> These authors contributed equally to this work

Abstract: Dengue is a serious mosquito-transmitted disease caused by the dengue virus (DENV). Rapid and reliable diagnosis of24DENV infection is urgently needed in dengue-endemic regions. We describe here the performance evaluation of the CE-marked25VIDAS® dengue immunoassays developed for the automated detection of DENV NS1 antigen, and anti-DENV IgM and IgG anti-26bodies. A multicenter concordance study was conducted in 1296 patients from dengue-endemic regions in Asia, Latin America, and27Africa. VIDAS® dengue results were compared to those of competitor enzyme-linked immunosorbent assays (ELISA). The VIDAS®28dengue assays showed high precision (CV ≤ 10.7%) and limited cross-reactivity (≤ 15.4%) with other infections. VIDAS® DENGUE29NS1 Ag showed high positive and negative percent agreement (92.8% PPA, 91.7% NPA) in acute patients within 0–5 days of symptom30onset. VIDAS® Anti-DENGUE IgM and IgG showed a moderate to high concordance with ELISA (74.8% to 90.6%) in post-acute and31recovery patients. PPA was further improved in combined VIDAS® NS1/IgM (96.4% in 0–5 days acute patients) and IgM/IgG (91.9%32in post-acute patients) tests. Altogether, the VIDAS® dengue NS1, IgM and IgG assays performed well, either alone or in combination,33and should be suitable for the accurate diagnosis of DENV infection in dengue-endemic regions.34

Keywords: dengue diagnosis; DENV; NS1 antigen; IgM and IgG antibodies; ELISA; VIDAS®

## 1. Introduction

Dengue is a mosquito-transmitted disease caused by one of the four dengue virus (DENV) serotype (DENV-1 to 38 DENV-4) [1,2]. With an estimated 96 million annual symptomatic infections, spreading mainly in Asia (70%), Africa 39 (16%) and the Americas (14%), dengue disease is a major public health concern [2–5]. The course of the disease ranges 40 from mild to severe, with an early febrile (acute) phase lasting 2-7 days followed by a critical phase that may either 41 worsen, evolving to a life-threatening course (severe dengue), or improve to full recovery usually within 1–2 weeks 42 43 [1,2,5]. In the absence of specific antiviral therapy, supporting care can effectively control severe dengue progression [1,2,5]. Administration of supportive care and other management protocols highly depend on early and reliable dengue 44 diagnosis. Early dengue diagnosis based on clinical manifestations is challenging, as early symptoms do not differenti-45 ate between dengue and other febrile diseases [1,2,5,6]. Beside individual patient management, reliable and rapid DENV 46

37

35

infection diagnosis is crucial to monitor and control dengue outbreaks in dengue-endemic regions [1,2,5,6]. Therefore, there is an urgent need for easy-to-use, rapid and accurate DENV-specific diagnostic assays.

Current guidelines recommend detecting circulating DENV RNA by reverse-transcription PCR (RT-PCR) and/or 49 the secreted viral non-structural protein 1 (NS1) antigen by immunoassay within the first 5-7 days of illness (acute 50 phase) to confirm DENV infection [5,7,8]. Following the acute phase, the detection of anti-DENV immunoglobulin M 51 (IgM) and/or G (IgG) using an immunoassay, such as enzyme-linked immunosorbent assay (ELISA) or immuno-chro-52 matographic rapid diagnostic test (RDT), is highly suggestive of a prior (primary or secondary) DENV infection [5,7,8]. 53 Because of the kinetics of response of these different markers (DENV RNA, DENV NS1 antigen, anti-DENV IgM and 54 IgG), their combined testing can increase the sensitivity of diagnosis, by extending the DENV diagnostic window 55 [1,2,5,7–16]. 56

RDT have been widely implemented in field settings. They are easy to use and rapid (about 20 minutes to inter-57 pretation). Their visual interpretation is however operator-dependent [17] and they lack in sensitivity [9,12,16,18–23]. 58 ELISA are more sensitive than RDT [9,12,16,18–23] but their manual execution limits their routine implementation in 59 field settings, notably at time of dengue outbreaks. We recently described the performance of three VIDAS® dengue 60 prototype assays developed for the detection of DENV NS1 antigen and anti-DENV IgM and IgG antibodies [24]. 61 VIDAS<sup>®</sup> dengue are fully automated immunoassays intended as an aid in the diagnosis of DENV infection in sympto-62 matic patients. The three VIDAS® dengue assays can be tested in parallel or applied independently. They are rapid (40-63 60 minutes to result), easy to use, and easy to interpret (positive or negative) with no equivocal zone. Prototype perfor-64 mance was evaluated in 91 Lao patients with acute DENV infection. We showed that VIDAS® dengue prototypes per-65 formed well, in comparison to manual competitor ELISA, both in adults and children, and that they outperformed RDT 66 in the diagnosis of acute DENV infection [24]. 67

The aim of this international, multicenter study was to evaluate the clinical performance of the three CE-marked 68 VIDAS® dengue immunoassays VIDAS® DENGUE NS1 Ag (DEAG), VIDAS® Anti-DENGUE IgM (DENM) and VIDAS® 69 Anti-DENGUE IgG (DENG) in the main dengue-endemic regions of the world (Asia, Latin America and Africa). A total 70 of 1296 samples of patients with suspected DENV infection were tested with the VIDAS® dengue assays and compared 71 to manual competitor ELISA. Results were interpreted using a stage-based algorithm considering the outcome of the 72 three dengue NS1, IgM and IgG assays, and defining different stages of DENV infection (acute, post-acute and recovery) 73 as well as a naïve status (i.e., patients with other febrile illnesses). Furthermore, we evaluated the analytical performance 74 (precision, cross-reactivity) of the three VIDAS® dengue immunoassays. Altogether, this multicenter study demon-75 strated that the VIDAS® dengue NS1, IgM and IgG assays performed well, either alone or in combination, and therefore 76 that they should be suitable for the accurate diagnosis of DENV infection in febrile patients of dengue-endemic regions. 77

# 2. Materials and Methods

## 2.1. Patients and Samples

A total of 1636 sera were collected between September 2015 and October 2020 in patients with a suspected DENV 80 infection, presenting at the hospital with one or more of the following symptoms: fever, headache, diarrhea, myalgia, 81 arthralgia, retro-orbital pain, thrombocytopenia, edema, rash, and nausea (Figure 1). Samples were collected prospectively or retrospectively in several dengue-endemic regions, including Asia (India, Vietnam, The Philippines), Latin 83 America (Brazil, Peru, Honduras, Dominican Republic) and Africa (Burkina Faso) and tested in central laboratories at 84 three distinct sites, as described in Table 1.

Table 1. Study samples

Site	Collection site	Samples	Collection time	Testing site
1	Hôpital Sainte Camille & Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso	Prospective cohort Adults and children	June 2020 – October 2020	Institut de Recherche en Sciences de la Santé (IRSS), Ouagadougou, Burkina Faso

86

78

79

47

2	Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto, Brazil	Retrospective & prospective cohorts <sup>1</sup> Adults	February 2019 – August 2020	Laboratório de Pesquisas em Virologia, FAMERP, São José do Rio Preto, Brazil
3	India, Vietnam, The Philippines, Peru, Honduras, and Dominican Republic	Retrospective cohort <sup>2</sup> Adults and children	September 2015 – September 2020	Clinical Affairs Laboratory, bioMérieux, Marcy l'Etoile, France

<sup>1</sup> Due to the COVID-19 pandemic, only two samples were collected prospectively; most samples were from a retrospective cohort
 collected during the 2019 dengue epidemic outbreak in Brazil. <sup>2</sup> Samples purchased from Boca Biolistics (Pompano Beach, Florida,
 USA), Discovery Life Sciences (Huntsville, Alabama, USA) and Atreide Biosamples (Hannover, Germany).

All collected sera ( $\geq$  1.5 ml) were aliquoted to allow testing with the different assays on the same freeze/thaw cycle. 91 Aliquots were frozen at the collection site, transported frozen under controlled conditions, and stored frozen at -20°C 92 until testing. This study was conducted in adherence to the guidelines of the Declaration of Helsinki, and approved by 93 the respective institutional review board at each institution (Comité d'Éthique pour la Recherche en Santé [CERS], Min-94 istère de la Santé, Ministère de l'Enseignement Supérieur, de la Recherche Scientifique et de l'Innovation, Burkina Faso, 95 No. 2020-4-076, dated 8 April 2020; Ethics Committee for Research on Human Beings of the Faculty of Medicine of São 96 José do Rio Preto, FAMERP, Brazil, No. 4.032.814, dated 18 May 2020 for the prospective collection and No. 97 02078812.8.0000.5415, dated 27 May 2019 for the retrospective collection). Purchased samples were collected and ap-98 proved for use for research purposes by the respective commercial providers (Boca Biolistics, Discovery Life Sciences 99 and Atreide Biosamples). All participants, or a parent or legal guardian in case of children, gave informed consent 100 before the start of the study. 101

Precision experiments were conducted using characterised negative and positive samples (bioMérieux collection). 102 Cross-reactivity experiments were performed using samples collected from patients with other potentially interfering 103 infections (bioMérieux collection) or from contrived samples generated from characterised negative samples. Negative 104 samples were provided by the French blood bank (Etablissement Français du Sang [EFS], La Plaine Saint-Denis, France). 105 Each volunteer donor signed a written informed consent for the use of blood for research purposes. EFS obtained from 106 the French ministry of research the authorization to collect and transfer samples to partners (Ministère de l'Enseignement Supérieur, de la Recherche et de l'Innovation, reference AC-2017-2958). 108

# 2.2. Study Design and Definitions

This multicenter study aimed to evaluate the diagnostic performance of VIDAS® dengue assays (bioMérieux SA,110Marcy-l'Étoile, France) detecting DENV NS1 antigen (VIDAS® DENGUE NS1 Ag) and anti-DENV IgM and IgG anti-111bodies (VIDAS® Anti-DENGUE IgM and VIDAS® Anti-DENGUE IgG, respectively), in terms of positive percent agree-112ment (PPA) and negative percent agreement (NPA) with competitor ELISA used as comparative method (Table 2).113

Competitor ELISA	Name of assay	Provider	
	Dengue NS1 Antigen DxSelect <sup>™</sup>	Focus Diagnostics, DiaSorin Molecular LLC, Cypress, CA, USA	
<b>NS1</b> <sup>1</sup>	(EL1510; IfU Rev. C)		
	DENV Detect <sup>TM</sup> NS1 ELISA	InRice International Inc. Scattle Washington LICA	
	(DNS1-1; IfU No. 900109-02)	indios international, inc., Seattle, Washington, USA	
	Panbio Dengue IgM Capture ELISA	Abbett Laboratorica Abbett Park II LISA	
	(01PE20)	Abbolt Laboratories, Abbolt Fark, IL, USA	
Igw -	DENV Detect IgM Capture ELISA	In Pice International Inc. Coattle Machington LICA	
	(DDMS-1)	indios international, inc., Seattle, Washington, USA	
IaC	Panbio Dengue IgG Indirect ELISA	Abbett I above torios Abbett Dauly II - LICA	
IgG	(01PE30)	Abbott Laboratories, Abbott Park, IL, USA	

Table 2. Competitor ELISA used for the concordance analysis with the VIDAS® Dengue assays

<sup>1</sup> Both NS1 ELISA were considered as equivalent based on respective instructions for use (IfU) and thus used interchangeably. <sup>2</sup> The
 <sup>1</sup> Both NS1 ELISA were used to interpret the competitor IgM ELISA results (considered positive when both were positive, and undetermined when at least one was discordant or equivocal).

114

109

Quantitative RT-PCR and serotyping assays detecting all four DENV serotypes' RNA were performed using the 118 CE-marked VIASURE Dengue Virus Real Time PCR Detection Kit (CerTest Biotec, Zaragoza, Spain; site 1), the CDC 119 DENV TaqMan® RT-qPCR assay (Center for Disease Control and Prevention, USA; site 2; [25,26]), and the CE-marked 120 RealStar Dengue RT-PCR (altona diagnostics GmbH, Hamburg, Germany; samples of site 3, outsourced to BIOMEX 121 GmbH, Heidelberg, Germany). 122

Patient samples were split as per algorithm, based on competitor ELISA and RT-PCR results. The dengue NS1, IgM 123 and IgG competitor ELISA test results, together with DENV RNA measurement by RT-PCR, were used to define the 124 stage of DENV infection (Table 3). Samples positive for DENV RNA and/or NS1 antigen were defined as Acute DENV 125 infection, regardless of the IgM and/or IgG ELISA results. Samples negative for both DENV RNA and NS1 antigen and 126 positive for both IgM and IgG ELISA were defined as Post-Acute DENV infection. Samples negative for DENV RNA, 127 NS1 antigen and IgM ELISA, but positive for IgG ELISA were defined as Recovery stage. Samples negative for all assays 128 (RT-PCR and competitor ELISA) were defined as naïve for DENV (i.e., from patients with other febrile illnesses). Sam-129 ples that did not meet these criteria or yielded undetermined test results were labelled as Unclassified (Table 3). 130

Table 3. Definition of DENV infection stages according to the competitor ELISA and RT-PCR test results.

Stage of DENV RT-PCR and/or NS1		IgM	IgG	
infection	competitor ELISA result <sup>1</sup>	competitor ELISA results <sup>2</sup>	competitor ELISA result <sup>3</sup>	
Naïve <sup>8</sup>	Negative <sup>4</sup>	Negative	Negative	
Acute	Positive <sup>5</sup>	Positive or negative	Positive or negative	
Post-Acute	Negative <sup>4</sup>	Positive	Positive	
Recovery	Negative <sup>4</sup>	Negative	Positive	
Unclassified	Negative <sup>4</sup> or Undetermined <sup>6</sup>	Positive or Undetermined 7	Negative or Undetermined 6	

<sup>1</sup> NS1 ELISA as described in Table 2. <sup>2</sup> IgM ELISA as described in Table 2; both assays must be concordant (negative or positive); 132 discordant competitor IgM ELISA results were excluded from the analysis (see Figure 1). <sup>3</sup> IgG ELISA as described in Table 2. <sup>4</sup> 133 Negative for both RT-PCR and NS1 ELISA. 5 Positive for RT-PCR and/or NS1 ELISA. 6 Undetermined defined as equivocal ELISA 134 135 (according to the manufacturer's definition). 7 Undetermined defined as either equivocal or discordant IgM ELISA (Panbio® Dengue IgM Capture ELISA and InBios DENV Detect IgM Capture ELISA). 8 Defines patients enrolled with a suspected DENV infection but 136 were negative in all dengue-specific assays (RT-PCR and competitor ELISA) and are thus likely to suffer from another febrile illness. 137

> 138 139

- 140

Unclassified samples were excluded from analyses considering the stage of infection but were included in analyses 141 based on the global population (Figure 1). Samples tested with all assays (VIDAS<sup>®</sup> dengue assays, competitor ELISA 142 and RT-PCR) were included in the final analysis (Figure 1). 143



**Figure 1.** Study Flow diagram. A total of 1636 samples of suspected DENV infection were collected, of which 1296 eligible samples tested with all assays (competitor ELISA, VIDAS<sup>®</sup> and PCR) were included in the analysis. Concordance analyses were conducted in the total population (n = 1296) and according to the DENV infection stages defined in Table 3 (n = 1205). An additional analysis on samples common to all immunoassays (n = 1138) is shown in Figure S2 and Table S5.

#### 2.3. VIDAS® Assays

The VIDAS® DENGUE NS1 Ag (DEAG; 423077), VIDAS® Anti-DENGUE IgM (DENM; 423078) and VIDAS® Anti-151DENGUE IgG (DENG; 423079) assays (bioMérieux SA, Marcy-l'Étoile, France) are automated qualitative two-step im-152munoassays developed for VIDAS® instruments [24]. The VIDAS® DENGUE NS1 Ag assay detects the dengue NS1153antigen of the four DENV serotypes. The VIDAS® Anti-DENGUE IgM and IgG assays detect IgM and IgG antibodies,154

145 146

- 147 148
- 149
- 150

respectively, recognising antigens of the four DENV serotypes, owing to the use of a recombinant tetravalent EDIIIT2 155 protein composed of the antigenic DENV-specific envelope domain III of the four DENV serotypes [24,27]. The three 156 VIDAS<sup>®</sup> dengue assays were performed and interpreted according to the instructions for use, as previously described 157 [24]. A test was interpreted as negative when the index value (i) was < 1.0 and positive when i  $\geq$  1.0. VIDAS<sup>®</sup> assays do not have equivocal test results. 159

#### 2.4. Competitor Assays

Competitor ELISA (Table 2) were conducted and interpreted according to the manufacturers' recommendations. 161 NS1 ELISA (FOCUS, InBios), IgM ELISA (Panbio) and IgG ELISA (Panbio) were interpreted as negative for result values 162 (index or immune status ratio [ISR]) < 0.9, positive for values > 1.1 and equivocal for 0.9–1.1 result values. IgM ELISA 163 (InBios) was interpreted as negative for ISR  $\leq$  1.65, positive for ISR  $\geq$  2.84 and equivocal for 1.65–2.84 ISR values. While 164 one NS1 ELISA (either FOCUS EL1510, Rev. C or InBios DNS1-1, version 900228-01, both considered equivalent accord-165 ing to their respective package insert) and one IgG ELISA (Panbio) were used as reference for the comparative analysis, 166 both IgM ELISA (Panbio and InBios) were performed and considered for the competitor test evaluation. Thus, the com-167 petitor IgM ELISA was interpreted as negative when both IgM ELISA (Panbio and InBios) were negative, positive when 168 both IgM ELISA were positive and undetermined when the Panbio and InBios IgM ELISA were discordant or equivocal 169 (Table 3). Samples with undetermined and equivocal competitor ELISA test results for a particular marker were ex-170 cluded from the concordance analysis for that marker (Figure 1). 171

# 2.5. Precision Experiments

Assay precision was evaluated according to the Clinical and Laboratory Standards Institute (CLSI) EP05-A3 guide-173 line [28], using characterised negative and positive (native or contrived) human sera that were aliquoted and had un-174 dergone one freeze-thaw cycle. Precision experiments were conducted at the Clinical Affairs Laboratory, bioMérieux 175 (Marcy l'Etoile, France). Within-run precision (repeatability) and within-laboratory precision (between-lot reproduci-176 bility) of the VIDAS® Dengue NS1 Ag, Anti-IgM and Anti-IgG assays was determined using three samples each: one 177 (high) negative and two (low and moderate) positive. Samples were run in duplicate on one VIDAS® instrument, twice 178 a day over 10 days (with an instrument calibration every second day), using two assay lots, thus generating 80 meas-179 urement values per sample (240 measurement values per VIDAS® Dengue assay). A visual data integrity check was 180 performed to identify possible outliers. Visually discordant results were confirmed to be statistical outliers using the 181 Generalized Extreme Studentized Deviate (ESD) test with a 1%  $\alpha$  risk. In case of confirmed outlier, the test was repeated, 182 and the valid result was used for precision calculation only if a definite root cause was identified. Variance was ex-183 184 pressed as standard deviation (SD) and coefficient of variation (CV).

#### 2.6. Cross-reactivity Experiments

Cross-reactivity experiments were performed in adherence to the CLSI EP07-Ed3 guideline [29] at the Clinical Affairs Laboratory, bioMérieux (Marcy l'Etoile, France) using either contrived samples or native samples from patients with other potentially interfering infections tested positive either for the respective pathogen or for the respective pathogen-specific antigen, RNA, IgM, IgG or total antibodies. 189

Contrived samples were generated for evaluating cross-reactivity with the VIDAS® Dengue NS1 Ag assay, by spiking defined amounts (10, 25, 50 ng/ml final concentration) of commercially available recombinant or inactivated native antigens (The Native Antigen Company, Oxford, UK; Meridian Bioscience, Cincinnati, Ohio, USA) into samples tested negative with the competitor NS1 ELISA (InBios DENV Detect<sup>™</sup> NS1 ELISA or FOCUS DENGUE NS1 Antigen DxSelect<sup>™</sup>). PCR- or antigen-positive HBV, HCV and SARS-CoV-2 samples were used to test the cross-reactivity with the VIDAS® Dengue NS1 Ag assay.

Samples used for evaluating the cross-reactivity with VIDAS® Anti-Dengue IgM were positive for pathogen-spe-196cific IgM, except for IAV/IBV and HIV, which were positive for pathogen-specific total antibodies, HCV samples, which197were positive for either anti-HCV IgG or anti-HCV total antibodies, ZIKV samples, which were positive for either anti-198ZIKV IgM or anti-ZIKV IgG antibodies, and *Plasmodium falciparum* samples which were positive for the pathogen itself.199

Samples used for evaluating the cross-reactivity with VIDAS<sup>®</sup> Anti-Dengue IgG were positive for pathogen-specific IgG, except for IAV/IBV, HBV and HIV, which were positive for pathogen-specific total antibodies, HCV samples, 201 which were positive for either anti-HCV IgG or anti-HCV total antibodies, ZIKV samples, which were positive for either 202 anti-ZIKV IgM or anti-ZIKV IgG antibodies, Yellow Fever samples, which were defined by the detection of neutralising 203 antibodies, and *Plasmodium falciparum* samples, which were positive for the pathogen itself. 204

185

160

The dengue-negative status of all samples was determined using the respective competitor ELISA: NS1 ELISA for205cross-reactivity with VIDAS® Dengue NS1 Ag, Panbio Dengue IgM ELISA for cross-reactivity with VIDAS® Anti-Dengue IgG, and Panbio Dengue IgG ELISA for cross-reactivity with VIDAS® Anti-Dengue IgG.206207

Cross-reactivities were tested in singlicate using three lot each of the VIDAS® Dengue NS1 Ag, Anti-Dengue IgM and Anti-Dengue IgG assays, on three instruments of the VIDAS® family. In case of a positive test result, the assay was repeated in duplicate on one VIDAS® instrument. A total of 68, 259 and 167 samples with other potentially interfering 210 infections were tested on the VIDAS® Dengue NS1 Ag, VIDAS® Anti-Dengue IgM, and VIDAS® Anti-Dengue IgG assays, respectively. 212

#### 2.7. Statistical Analyses

Assay precision was assessed in adherence to the CLSI EP05-A3 guideline [28] by a component-of-variance analysis 214 for nested design (Restricted Maximum Likelihood) using the SAS Enterprise Guide 7.12 software. 215

213

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

Concordance analyses were conducted between the VIDAS<sup>®</sup> assays and competitor ELISA used as comparative method. Accordingly, the terms "positive percent agreement" (PPA) and "negative percent agreement" (NPA) were used instead of "sensitivity" and "specificity", respectively. Concordance analyses (PPA, NPA and overall percent agreement) were performed in adherence to the CLSI EP12-A2 guideline [30]. The 95% confidence intervals (95% CI) were computed, either as Wilson Score Confidence Interval if the percentage agreement was in the range ]5%, 95%[ or as Exact Binomial Confidence Interval otherwise, using the SAS Enterprise Guide 7.12 software.

Positive agreement between the dengue NS1 assays (whether VIDAS<sup>®</sup> or competitor ELISA) and RT-PCR, corresponding to assay sensitivity relative to RT-PCR set as gold standard, was also evaluated, and the respective 95% CI were computed as above. The sensitivity of both DENV NS1 assays were compared by calculating the Cohen's kappa coefficient ( $\kappa$ ); a  $\kappa$  = 0.81 – 0.99 was interpreted as near-perfect agreement between the two NS1 assays, indicating that the difference in sensitivity to RT-PCR is not statistically significant.

VIDAS<sup>®</sup> dengue index values were displayed as Tukey box plots, in the global population and according to the DENV infection stage defined by our algorithm (Table 3), using GraphPad Prism 5.04 (GraphPad Software, San Diego, CA, USA).

## 3. Results

#### 3.1. Patients' Characteristics

Out of 1636 patients with suspected DENV infection recruited at multiple dengue-endemic regions worldwide,2321296 eligible and tested with all assays (VIDAS® assays, competitor ELISA and RT-PCR) were included in the analysis233(Figure 1). 1205/1296 (93.0%) samples were assigned a DENV infection stage (Table 4) based on the test results of RT-234PCR and the competitor ELISA (Table 3) and were included in the analysis per DENV infection stage (Figure 1).235

Between 392 and 480 samples were tested at each of the three testing sites (Table 4). Included patients were mainly 236 adults (1258/1296 [97.1%] ≥ 18 years-old), with a median age of 32 years, and 57.2% were female (Table 4). Among the 237 154 patients with a positive dengue-specific RT-PCR test result, most were of the DENV-1 (74/154 [48.0%]) and DENV-238 2 (72/154 [46.8%]) serotype (Table 4). The distribution of patients according to the time post symptom onset at inclusion 239 is shown for the global population (Table 4) and for each DENV infection stage (Table S1). As expected, most (258/281 240 [91.8%]) acute samples (NS1 ELISA- and/or RT-PCR-positive) had a documented time from symptom onset of 0-8 days 241 and most (101/123 [82.1%]) post-acute samples (NS1 ELISA- and RT-PCR-negative, IgM and IgG ELISA-positive) of 6-242 8 days (Table S1). The observation that most (546/626 [87.2%]) recovery samples (NS1 ELISA- and RT-PCR-negative, 243 IgM ELISA-negative, IgG ELISA-positive) and most (160/175 [91.4%]) naïve samples (negative for RT-PCR and all three 244 dengue ELISA) according to our algorithm were documented with an early time from symptom onset (0-8 days; Table 245 S1) indicate that these patients suffer from a febrile illness other than DENV. 246

Study population, N (%)	1296 (100.0%)
Study population according to the testing site, N (%)	
Site 1 (Burkina Faso; sample collection and testing)	480 (37.0%)
Site 2 (Brazil; sample collection and testing)	392 (30.3%)
Site 3 (France; externally acquired sample testing)	424 (32.7%)
Age in years, median (range)	32.0 (5-88)
Sex, N (%)	
Female	741 (57.2%)
Male	555 (42.8%)
RT-PCR-positive samples, N (%)	154 (11.9%)
Serotype distribution among RT-PCR-positive samples, N (%)	
DENV-1	74/154 (48.0%)
DENV-2	72/154 (46.8%)
DENV-3	6/154 (3.9%)
DENV-4	2/154 (1.3%)
Sample distribution according to time from symptom onset, N (%)	
0 – 3 days	477 (36.8%)
4 – 5 days	228 (17.6%)
6 – 8 days	456 (35.2%)
9 – 15 days	78 (6.0%)
16 days – 1 month	34 (2.6%)
>1 month	16 (1.2%)
Unknown	7 (0.6%)
DENV infection stage $^{1}$ , N (%)	
Acute	281 (21.7%)
Post-Acute	123 (9.5%)
Recovery	626 (48.3%)
Naïve	175 (13.5%)
Unclassified	91 (7.0%)

<sup>1</sup> According to the RT-PCR- and competitor ELISA-based algorithm (Table 3).

#### 3.2. VIDAS® Dengue Test Result Description

Index distribution of the VIDAS® Dengue NS1 Ag, Anti-dengue IgM and Anti-dengue IgG assays is shown in259Figure S1, and the respective index medians and interquartile ranges are presented in Table S2. In line with the algo-<br/>rithm-based classification (Table 3), higher VIDAS® Dengue NS1 Ag index values were observed in acute samples (Fig-<br/>ure S1). VIDAS® Dengue NS1 Ag index values were also higher when considering the samples collected within the first<br/>five days post symptom onset (D0-5) compared to the whole acute category. Similarly, VIDAS® Anti-dengue IgM index<br/>values were highest in acute and post-acute samples, and VIDAS® Anti-dengue IgG index values were highest in acute,<br/>post-acute and recovery samples (Figure S1).269

In agreement with these index value results, evaluation of the qualitative VIDAS<sup>®</sup> Dengue test results showed a high proportion (80.4%) of positive VIDAS<sup>®</sup> Dengue NS1 Ag tests in acute samples within the first five days after symptom onset (D0-5), and a moderate to high proportion of positive VIDAS<sup>®</sup> Anti-dengue IgM and Anti-dengue IgG tests in post-acute samples (74.8% and 80.5%, respectively) (Table S3). Interestingly, the proportion of positive VIDAS<sup>®</sup> NS1 269 and/or IgM combined tests (NS1/IgM) raised to 86.5% in D0-5 acute samples and that of positive VIDAS<sup>®</sup> IgM and/or 270 IgG combined tests (IgM/IgG) raised to 91.9% in post-acute samples (Table S3). 271

# 3.3. Analytical Performance of the VIDAS® Dengue Assays

## 3.3.1. Assay Precision

Assay precision of the three VIDAS<sup>®</sup> Dengue NS1 Ag, Anti-dengue IgM and Anti-dengue IgG assays was evaluated 274 on negative and positive samples. The coefficient of variation (CV) did not exceed 7.5% for repeatability (within-run precision) and 10.7% for within-laboratory (between-lot) precision, across the three VIDAS<sup>®</sup> assays (Table 5). 276

257

258

272

VIDAS® dengue	Sample	Total number of	Mean	Repeatability (within-run precision)		Within-laboratory precision <sup>2</sup>	
assay		meusurements	macx	SD	CV (%)	SD	CV (%)
	A (negative, high)	<b>79</b> <sup>1</sup>	0.62	0.05	7.5	0.05	8.2
NS1	B (positive, low)	80	1.26	0.06	5.1	0.07	5.4
	C (positive, moderate)	80	1.71	0.07	4.1	0.08	4.9
	A (negative, high)	80	0.82	0.02	3.0	0.09	10.7
IgM	B (positive, low)	80	1.16	0.03	2.7	0.09	8.1
	C (positive, moderate)	80	1.56	0.03	1.8	0.11	7.2
	A (negative, high)	80	0.73	0.03	4.4	0.04	5.8
IgG	B (positive, low)	80	1.28	0.05	4.1	0.07	5.7
-	C (positive, moderate)	80	1.44	0.07	4.5	0.09	6.4

Table 5. Precision of the VIDAS<sup>®</sup> Dengue NS1, IgM and IgG assays.

<sup>1</sup> An outlier was confirmed by a Generalized Extreme Studentized Deviate (ESD) test ( $\alpha = 1\%$ ) and excluded from the precision calculation; <sup>2</sup> Between-lot reproducibility. Abbreviations: SD, standard deviation; CV, coefficient of variation.

#### 3.3.2. Assay Cross-reactivity

Analytical specificity of the three VIDAS® Dengue assays was evaluated using samples from patients with other proven infections and confirmed negative with the respective dengue ELISA reference tests. Cross-reactivity was measured as the proportion of positive VIDAS<sup>®</sup> Dengue NS1, IgM and IgG assays (Table 6). 283

Table 6. Cross-reactivity of human contrived samples or native samples from patients with other infections potentially interfering 284 with the VIDAS<sup>®</sup> dengue NS1, IgM and IgG assays. 285

	Proportion of cross-reactions with VIDAS®			
Potentially interfering infections	_	Dengue assays		
	NS1	IgM	IgG	
Herpes simplex virus (HSV1/2)	0/6 1	2/13	3/14	
Varicella zoster virus (VZV)	0/3 1	4/15	0/10	
Cytomegalovirus (CMV)	0/3 1	4/17	0/10	
Epstein-Barr virus (EBV)	0/3 1	3/14	2/15	
Influenza virus (IAV/IBV)	nd	2/11	2/10	
Borrelia burgdorferi	nd	2/14	nd	
Plasmodium falciparum	0/3 1	3/10	0/10	
Leptospira	nd	3/12	nd	
Chikungunya virus (CHIKV)	0/3 1	0/13	0/7	
West Nile virus (WNV)	0/3 1	1/18	2/9	
Yellow fever virus (YFV)	0/3 1	2/21	0/14	
Zika virus (ZIKV)	0/3 1	1/14	0/8	
Hepatitis A virus (HAV)	nd	1/15	nd	
Hepatitis B virus (HBV)	0/10	2/14	0/7	
Hepatitis C Virus (HCV)	1/9	3/14	1/14	
Parvovirus B19	nd	4/14	0/10	
Human immunodeficiency virus (HIV)	nd	1/14	2/9	
HIV P24 antigen	0/9	nd	nd	
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	0/10	2/16	1/20	
Total (%)	1/68 (1.5%)	40/259 (15.4%)	13/167 (7.8%)	

<sup>1</sup>Contrived samples generated using volunteer donor samples tested negative with the competitor NS1 ELISA and spiked-in with 10, 25 or 50 ng/ml recombinant or inactivated native antigens. Abbreviation: nd, not determined.

280 281

278

279

282

286

Overall, cross-reactivity with the VIDAS<sup>®</sup> Dengue NS1 Ag assay was very low (1/68 [1.5%]), with one reactivity 288 with a native sample positive for hepatitis C virus (HCV) and none with samples of patients infected with severe acute 289 respiratory syndrome coronavirus 2 (SARS-CoV-2) or with other flaviviruses such as West Nile virus, yellow fever virus 290 and Zika virus (Table 6). Cross-reactivity with the VIDAS® Anti-dengue IgG assay was higher (13/167 [7.8%]) and in-291 volved mainly samples of patients positive for IgG or total antibodies directed against other viruses (HSV, EBV, influ-292 enza, HCV, HIV), including the flavivirus West Nile virus (2/9) and the coronavirus SARS-CoV-2 (1/20) (Table 6). Cross-293 reactivity with the VIDAS<sup>®</sup> Anti-dengue IgM assay was the highest (40/259 [15.4%]). It involved samples of patients 294 positive for antibodies against other viruses (VZV, CMV, EBV, HCV, parvovirus B19), bacteria (leptospira) and parasites 295 (Plasmodium falciparum), and to some extent against the flaviviruses West Nile virus (1/18), yellow fever virus (2/21) and 296 Zika virus (1/14), as well as the coronavirus SARS-CoV-2 (2/16) (Table 6). 297

## 3.4. Clinical Performance of the VIDAS® Dengue Assays

## 3.4.1. Clinical Sensitivity

Quantitative RT-PCR is often used as gold standard for the detection of acute DENV infection [20,24,31]. To eval-300 uate the sensitivity of the VIDAS® Dengue NS1 Ag assay, its positive agreement with DENV-specific RT-PCR set as 301 gold standard was evaluated in acute samples and compared to that of the competitor NS1 ELISA (Table 7). No statis-302 tically significant differences were observed between the clinical sensitivity of VIDAS® DENGUE NS1 Ag assay and 303 that of the NS1 ELISA, on all acute samples (Cohen's kappa coefficient  $\kappa$  = 0.885, *p* < 0.0001) and on acute samples 304 collected within the first five days post onset of symptoms (D0-5) (Cohen's kappa coefficient  $\kappa = 0.867$ , p < 0.0001). 305 Sensitivity of the VIDAS<sup>®</sup> Dengue NS1 Ag assay was higher in the D0-5 acute samples (81/106 [76.4%]) compared to all 306 acute samples (98/153 [64.1%]) (Table 7). 307

Table 7. Positive agreement of t	ne VIDAS <sup>®</sup> and compe	titor ELISA NS1 antig	en assavs with RT-PCR
rubic // i obilive ugreement of t	ie vibrio una compe	the building	cirabbayo minini i cir

Reference	Donulation		VIDAS <sup>®</sup> NS1	NS1 ELISA <sup>2</sup>		
test	ropulation	$n/N^{1}$	% [95% CI]	$n/N^{1}$	% [95% CI]	
RT-PCR	All acute samples	98/153	64.1% [56.2-71.2]	102/153	66.7% [58.9-73.6]	
	D0-5 acute samples	81/106	76.4% [67.5-83.5]	82/106	77.4% [68.5-84.3]	

<sup>1</sup>*n*/*N* is the ratio of the number of samples positive for the respective immunoassays (VIDAS® NS1, NS1 ELISA) to the number of RT-PCR-positive samples. To calculate sensitivity on the same cohort, one sample equivocal with the NS1 ELISA was excluded from the analysis. <sup>2</sup> InBios DENV Detect<sup>TM</sup> NS1 ELISA or FOCUS DENGUE NS1 Antigen DxSelect<sup>TM</sup>. VIDAS® DENGUE NS1 Ag assay and NS1 ELISA showed a near-perfect agreement in their sensitivity to RT-PCR, with Cohen's kappa coefficients  $\kappa = 0.885$  (all acute samples) and  $\kappa = 0.867$  (D0-5 acute samples) (*p* < 0.0001 in both cases). Abbreviations: CI, confidence interval; D0-5, 0-5 days post symptom onset. 314

## 3.4.2. Clinical Specificity

To estimate the true-negative rate (specificity) of the three VIDAS® Dengue assays, their negative agreement with 316 the respective competitor ELISA was calculated in the population of naïve patients. Naïve patients are defined as subjects presenting clinical symptoms consistent with a DENV infection (i.e., the intended population of the VIDAS® Dengue assays) but tested negative by RT-PCR and for the three markers (NS1, IgM and IgG) by the competitor ELISA 319 (Table 3). The negative agreement of the VIDAS® Dengue assays with the competitor ELISA was high in the population 320 naïve for DENV, with 152/175 (86.9%) for VIDAS® Anti-dengue IgM, 156/175 (89.1%) for VIDAS® Anti-dengue IgG, and 321 175/175 (100.0%) for VIDAS® Dengue NS1 Ag (Table 8). 322

 Table 8. Negative agreement of the VIDAS<sup>®</sup> Dengue assays with the competitor ELISA tested on study samples defined as naïve.

Donulation	VIDAS <sup>®</sup> NS1		VIDAS® IgM		VIDAS <sup>®</sup> IgG	
ropulation	$n/N^{1}$	% [95% CI]	$n/N^{1}$	% [95% CI]	$n/N^{1}$	% [95% CI]
Naïve samples <sup>2</sup>	175/175	100.0% [97.9-100.0]	152/175	86.9% [81.1-91.1]	156/175	89.1% [83.7-92.9]

 $<sup>^{1}</sup>n/N$  is the ratio of the number of samples negative for the respective VIDAS<sup>®</sup> immunoassays (NS1, IgM, IgG) to the number of naïve 324 samples.  $^{2}$  Tested negative by the dengue NS1, IgM and IgG ELISA and by RT-PCR, hence corresponding to patients with other 6brile illnesses. Abbreviation: CI, confidence interval. 326

323

328

308

315

298

<sup>327</sup> 

## 3.4.3. Concordance of DENV Infection Classification

Overall agreement of the DENV infection classification by the VIDAS® Dengue assays with that by the competitor ELISA (as defined using the algorithm presented in Table 3), is shown in Table 9. Acute classification by the VIDAS® Dengue test results was in strong agreement with the classification by the competitor ELISA, with up to 156/163 (95.7%) concordant classification for the early (D0-5) acute stage (Table 9). Classification of naïve samples was also highly con-cordant between VIDAS® and competitor ELISA (142/175 [81.1%]) (Table 9). Concordance of post-acute (78/123 [63.4%]) and recovery (430/626 [68.7%]) classifications by VIDAS® and competitor ELISA was moderate (Table 9). Since these stages are defined by IgM and/or IgG test positivity, partial concordance suggests differences in IgM and/or IgG test results between VIDAS<sup>®</sup> and competitor ELISA. This is supported by the observation that discordant post-acute and recovery classifications were mainly classified in the respective category (i.e., most discordant post-acute were classified as recovery and vice versa by VIDAS®) (Table S4). Concordance of unclassified samples was very low (2/91 [2.2%]; Table 9). This was expected given that equivocal and undetermined test interpretations by the competitor ELISA does not occur with the VIDAS<sup>®</sup> assays (which are interpreted as either positive or negative). 

Table 9. Concordance of the infection stage classification by the VIDAS®-based vs. the competitor ELISA-based algorithm

Stage of DENIX infection 2	Agreement			
	$n/N^{-1}$	% [95% CI]		
Acute (all)	249/281	88.6% [84.4-91.8]		
Acute (D0-5)	156/163	95.7% [91.4-98.3]		
Post-Acute	78/123	63.4% [54.6-71.4]		
Recovery	430/626	68.7% [65.0-72.2]		
Naïve	142/175	81.1% [74.7-86.2]		
Unclassified	2/91	2.2% [0.3-7.7]		

 $\frac{1}{n}$  is the ratio of the number of samples whose classification using the defined rules (Table 3) by the VIDAS<sup>®</sup> assays is concordant 343 with that by the competitor ELISA, to the number of samples classified by the competitor ELISA. <sup>2</sup> According to the RT-PCR- and competitor ELISA-based algorithm (Table 3). Abbreviations: CI, confidence interval; D0-5, 0-5 days post symptom onset. 345

3.4.4. Assay Concordance in the Total Study Population and per DENV Infection Stage

We next evaluated the positive (PPA) and negative (NPA) percent agreement of the three VIDAS<sup>®</sup> dengue assays with the respective competitor ELISA (Table 10).

The PPA (95% CI) of the VIDAS® Dengue NS1 Ag assay was 83.4% (78.0-87.7) in all acute samples, reaching 92.8%349(87.2-96.0) in the D0-5 acute population (Table 10). The respective NPA (95% CI) was 99.2% (98.5-99.7) in the total population, ranging from 91.7% (74.2-97.7) in D0-5 acute to 100.0% (97.0-100.0) in post-acute samples (Table 10).351

The PPA and NPA of the VIDAS<sup>®</sup> Anti-dengue IgM assay were overall moderate, with a PPA (95% CI) of 80.1% (74.9-84.4) and a NPA (95% CI) of 78.7% (75.8-81.2) in the total population (Table 10).

The PPA (95% CI) of the VIDAS<sup>®</sup> Anti-dengue IgG assay was 85.8% (83.6-87.7) in the total population, ranging from 73.9% (68.2-78.8) in acute to 90.6% (88.0-92.6) in recovery samples. Its NPA (95% CI) was 86.3% (80.8-90.4) in the total population, with a minimum of 40.0% (16.8-68.7) in D0-5 acute samples (Table 10).

VIDAS®		Positi	ive Agreement Negat		ive Agreement	Overal	Overall Agreement	
dengue assay	Population	$n/N^{1}$	% [95% CI]	$n/N^{1}$	% [95% CI]	$n/N^{1}$	% [95% CI]	
	Total	191/229	83.4% [78.0-87.7]	1058/1066	99.2% [98.5-99.7]	1249/1295	96.4% [95.3-97.4]	
	Acute (all)	191/229	83.4% [78.0-87.7]	49/51	96.1% [86.5-99.5]	240/280	85.7% [81.1-89.3]	
NS1	Acute (D0-5)	128/138	92.8% [87.2-96.0]	22/24	91.7% [74.2-97.7]	150/162	92.6% [87.5-95.7]	
	Post-Acute	N/A	-	123/123	100.0% [97.0-100.0]	N/A	-	
-	Recovery	N/A	-	621/626	99.2% [98.1-99.7]	N/A	-	
	Total	213/266	80.1% [74.9-84.4]	689/876	78.7% [75.8-81.2]	902/1142	79.0% [76.5-81.2]	
	Acute (all)	120/142	84.5% [77.7-89.5]	57/72	79.2% [68.4-86.9]	177/214	82.7% [77.1-87.2]	
IgM	Acute (D0-5)	65/74	87.8% [78.5-93.5]	34/45	75.6% [61.3-85.8]	99/119	83.2% [75.5-88.8]	
	Post-Acute	92/123	74.8% [66.5-81.6]	N/A	-	N/A	-	
	Recovery	N/A	-	477/626	76.2% [72.7-79.4]	N/A	-	
	Total	940/1096	85.8% [83.6-87.7]	170/197	86.3% [80.8-90.4]	1110/1293	85.8% [83.8-87.6]	
	Acute (all)	195/264	73.9% [68.2-78.8]	10/17	58.8% [36.0-78.4]	205/281	73.0% [67.5-77.8]	
IgG	Acute (D0-5)	129/153	84.3% [77.7-89.2]	4/10	40.0% [16.8-68.7]	133/163	81.6% [74.9-86.8]	
	Post-Acute	99/123	80.5% [72.6-86.5]	N/A	-	N/A	-	
	Recovery	567/626	90.6% [88.0-92.6]	N/A	-	N/A	-	

**Table 10.** Concordance of the VIDAS® dengue assays with the respective competitor ELISA, in the global population and per stage370of DENV infection.371

 $^{1}$  *n*/*N* is the ratio of the number of samples for which VIDAS<sup>®</sup> assays are in agreement (positive, negative and overall) with the competitor ELISA (reference test) to the number of samples tested either positive or negative (and overall) with the competitor ELISA. Abbreviations: CI, confidence interval; D0-5, 0-5 days post symptom-onset; N/A, not applicable. 374

Concordance analyses based on the cohort common to the three VIDAS<sup>®</sup> dengue assays (Figure S2) yielded comparable results (Table S5). Moreover, concordance analyses according to time post symptom onset (instead of infection 376 stage, as defined by our algorithm), revealed comparable results (Table S6). Notably, the PPA of the NS1 assay was 377 highest (>90%) in the 0 – 5 days post symptom onset, and decreased afterward, as expected for this acute-phase marker 378 and in line with current guidelines [5,7,8]. 379

## 3.4.5. Positive Agreement of Combined NS1/IgM and IgM/IgG Tests

Combining NS1, IgM and IgG test results is known to improve both sensitivity and specificity of DENV infection 382 diagnosis, especially when patients present at different time points after symptom onset [5,7–10,13,14,22,24]. Thus, we evaluated the positive agreement of combined VIDAS® NS1/IgM and IgM/IgG test results in the total population and at relevant infection stages, i.e., acute stage for NS1/IgM and post-acute stage for IgM/IgG (Table 11). 385 PPA (95% CI) of combined NS1/IgM in the total population was 87.3% (83.5-90.3) (Table 11) *vs.* 83.4% (78.0-87.7) 386

PPA (95% CI) of combined NS1/IgM in the total population was 87.3% (83.5-90.3) (Table 11) *vs.* 83.4% (78.0-87.7) for NS1 and 80.1% (74.9-84.4) for IgM (Table 10). PPA (95% CI) of combined NS1/IgM in acute samples was 93.7% (89.9-96.1), reaching 96.4% (91.8-98.8) in D0-5 acute samples (Table 11) (*vs.* 92.8% [87.2-96.0] for NS1 and 87.8% [78.5-93.5] for IgM; Table 10).

PPA (95% CI) of combined IgM/IgG in the total population was 91.9% (90.1-93.4) (Table 11) *vs.* 80.1% (74.9-84.4) for IgM and 85.8% (83.6-87.7) for IgG (Table 10). The PPA (95% CI) of combined IgM/IgG in post-acute samples was 91.9% (85.7-95.5) (Table 11) *vs.* 74.8% (66.5-81.6) for IgM and 80.5% (72.6-86.5) for IgG (Table 10).

VIDACO donomo accan	Donulation	Positive Agreement			
vIDA5® dengue assay	ropulation	$n/N^{1}$	% [95% CI]		
	Total	316/362	87.3% [83.5-90.3]		
	Total (D0-5)	145/152	95.4% [90.7-98.1]		
1\51/1gm -	Acute (all)	223/238	93.7% [89.9-96.1]		
	Acute (D0-5)	134/139	96.4% [91.8-98.8]		
	Total	1011/1100	91.9% [90.1-93.4]		
Igivi/IgG °	Post-Acute	113/123	91.9% [85.7-95.5]		

**Table 11.** Positive agreement of combined NS1/IgM and IgM/IgG VIDAS® dengue assays with the respective competitor ELISA, in403the total, acute (NS1/IgM) and post-acute (IgM/IgG) stage of DENV infection.404

 $^{1}$  *n/N* is the ratio of the number of samples positive for the indicated combined VIDAS<sup>®</sup> Dengue assays (NS1- and/or IgM-positive; IgM- and/or IgG-positive) to the number of samples positive for the combined competitor ELISA. <sup>2</sup> PPA of VIDAS<sup>®</sup> NS1 and/or IgM 406 vs. competitor NS1 and/or IgM ELISA; <sup>3</sup> PPA of VIDAS<sup>®</sup> IgM and/or IgG vs. competitor IgM and/or IgG ELISA. Abbreviations: CI, 407 confidence interval; D0-5, 0-5 days post symptom-onset. 408

409

#### 4. Discussion

This multicenter study evaluated the diagnostic performance of three VIDAS<sup>®</sup> dengue immunoassays detecting 410 DENV NS1 antigen and Anti-DENV IgM and IgG antibodies, in comparison with commercial competitor ELISA. This 411 study is a follow-up of the recent performance evaluation study conducted in 91 Lao patients with acute dengue infection, using the respective VIDAS<sup>®</sup> dengue prototype assays [24]. A major strength of this study is the inclusion of a large 413 number of samples (n = 1296) covering most dengue-endemic regions around the world, including Asia (India, Vietnam, 414 The Philippines), Latin America (Brazil, Peru, Honduras, Dominican Republic) and Africa (Burkina Faso) [2,3].

The three VIDAS® dengue assays demonstrated high within-run and within-laboratory precision (CV < 11.0%). The 416 VIDAS<sup>®</sup> DENGUE NS1 Ag assay showed very low cross-reactivity (1.5%) with samples positive for other infection-417 specific antigens. The VIDAS® Anti-DENGUE IgM and IgG assays presented higher cross-reactivity (15.4% and 7.8%, 418 respectively) with samples positive for IgM or IgG directed against other pathogen-specific antigens, as previously 419 described for immunoassays [5,6,16,18,22,32-36]. These included cross-reactions with antibodies directed against other 420 flaviviruses (4/53 [7.5%] for IgM and 2/31 [6.5%] for IgG). These cross-reactivity rates were however in range with or 421 lower than those reported for other flavivirus IgM and IgG assays [34], including some of the competitor ELISA used 422 in this study. Notably, cross-reactivity of the VIDAS® Anti-DENGUE IgM and IgG assays with West Nile Virus (WNV)-423 positive samples was lower than that reported by the competitor IgM and IgG ELISA manufacturers (1/18 [5.6%] for 424 VIDAS® Anti-DENGUE IgM vs. 2/10 [20.0%] and 12/24 [50.0%] for IgM ELISA; 2/9 [22.2%] for VIDAS® Anti-DENGUE 425 IgG vs. 2/5 [40.0%] for IgG ELISA). Cross-reactivity with samples from SARS-CoV-2-infected patients (2/16 [12.5%] for 426 IgM and 1/20 [5.0%] for IgG) was also observed. Such cross-reactions were expected, in line with the recent demonstra-427 tion of shared antigenic similarity between DENV and SARS-CoV-2, resulting in cross-reactivity of the antibody re-428 sponse to both viruses [37-44]. Cross-reactivity of antibodies against DENV and SARS-CoV-2 was shown to be espe-429 cially high using rapid diagnostic tests (RDT), as opposed to ELISA [37,39-44], in line with the relatively low cross-430 reactivity rates with SARS-CoV-2 samples observed in this study using the VIDAS® Anti-DENV IgM and IgG assays. 431

Such antigenic similarity and cross-reactivity of immune responses of DENV and SARS-CoV-2 raise new diagnostic432challenges in DENV-endemic regions in this time of COVID-19 pandemics [38,42,45–47]. Indeed, the impact of antibody433cross-reactivity and/or of co-infection with DENV and SARS-CoV-2 on misdiagnosis but also on the immune response434of patients and consequently on the outcome of immunoassays, remains unexplored. Given the partial overlap of sample collection with the COVID-19 pandemics in our study, and without documented information on possible co-infections with SARS-CoV-2, the results presented here should be interpreted with caution, as a possible impact of the437COVID-19 pandemics cannot be excluded. Future studies should specifically explore this question.438

Clinical performance of the VIDAS® Dengue assays was assessed by measuring the sensitivity of the VIDAS® DEN-439 GUE NS1 Ag assay (positive agreement with RT-PCR set as gold standard), and by evaluating assay concordance (pos-440 itive and negative agreement with competitor ELISA). Sensitivity of the VIDAS® DENGUE NS1 Ag assay in the D0-5 441 acute population (76.4%) was similar to that observed in the adult Lao population (79.5%) at a comparable time from 442 symptom onset (median time of 4.5 days) [24]. Specificity of the three VIDAS® Dengue assays (negative agreement with 443 the respective competitor ELISA) in the intended population (i.e., patients with suspected DENV infection but classified 444 as naïve for DENV) was also comparable to that measured in an adult healthy population using the three VIDAS® 445 Dengue prototypes (86.9-100.0% vs. 96.1-100.0%, respectively) [24]. 446

Overall, concordance analyses revealed a good agreement of the VIDAS<sup>®</sup> Dengue assays with competitor ELISA. 447 As to DENV infection classification, the strong agreement (95.7%) of D0-5 acute stage classification by VIDAS® Dengue 448 assays using our staging algorithm is in line with the high PPA of the VIDAS® DENGUE NS1 Ag assay in the D0-5 acute 449 population (92.8%) and the comparable sensitivity of the VIDAS® DENGUE NS1 Ag and competitor NS1 ELISA (76.4% 450 vs. 77.4%) toward RT-PCR. The NPA of the VIDAS® DENGUE NS1 Ag assay was also very high, at all DENV infection 451 stages (91.7%-100.0%). Of note, in the adult acute Lao population, the PPA of the VIDAS® DENGUE NS1 Ag prototype 452 was slightly higher (98.0%) and the NPA slightly lower (87.5%) than in the current multicenter study [24]. This might 453 be in part due to the difference in sample number between both studies. 454

On the other hand, the moderate agreement of post-acute (63.4%) and recovery (68.7%) stage classification by 455 VIDAS® Dengue assays is in line with the partial concordance with competitor ELISA of the VIDAS® Anti-DENGUE 456 IgM assay (PPA of 74.8% in post-acute samples, NPA of 76.2% in recovery samples) and to some extent of the VIDAS® 457 Anti-DENGUE IgG assay (PPA of 80.5% in post-acute samples). These results indicate a higher discordance of IgM 458 and/or IgG test results between VIDAS® and competitor ELISA. 459

Assay concordance was improved in combined NS1/IgM test results at early (D0-5) acute stages of DENV infection (96.4% PPA), and in combined IgM/IgG test results post-acute (91.9% PPA), demonstrating the benefit of combining marker immunodetection using the VIDAS<sup>®</sup> Dengue assays to improve the sensitivity of diagnosis of DENV infection, as previously reported for other assays [5,9,10,13,24].

This study presents several limitations. First, despite the large number of collected samples (392 to 480 per site), 464 heterogeneity between testing sites were observed, notably in the distribution of infection stage, time post symptom 465 onset, and serotype distribution. This precluded subgroup analyses per site. Second, 146/154 (94.8%) samples were of 466 DENV-1 and DENV-2 serotypes. While DENV-1 and DENV-2 serotypes are predominant in most dengue-endemic re-467 gions worldwide [4], it is possible that our performance evaluation study is not representative of DENV-3 and DENV-468 4 serotypes. Given that all four DENV serotypes are known to co-circulate in a spatial and/or temporal manner [48], 469 and that assay performance might be serotype-dependent [6], additional studies should be conducted to confirm assay 470 performance in patients infected with DENV-3 and DENV-4 serotypes. Third, the choice of considering two competitor 471 IgM ELISA as comparator to the VIDAS® Anti-DENGUE IgM assay led to the exclusion of 152 samples from the IgM 472 analysis (because discordant between the two competitor IgM ELISA), which might have introduced a bias in the anal-473 ysis. Since the concordance analysis conducted on the common samples showed comparable performance results, such 474 bias is however unlikely. Fourth, as mentioned above, we cannot exclude an effect of the COVID-19 pandemics (via 475 cross-reactivity and/or co-infection interferences) on the VIDAS® Dengue assay performance evaluation, although the 476 impact might be limited in the context of a concordance analysis (assuming a similar impact on both compared assays). 477 Finally, the use of distinct and non-standardized RT-PCR and serotyping methods at the three testing sites might have 478 introduced a bias in the acute infection stage definition according to our algorithm, although this is unlikely given the 479 high sensitivity and specificity (90–100%) of commercial RT-PCR assays [1,5,8,9,13]. 480

#### 5. Conclusions

Altogether, this multicenter study conducted on a large number of samples representative of several dengue-endemic regions demonstrated a strong performance of the VIDAS® DENGUE NS1 Ag assay, either alone or in combination with the VIDAS® Anti-DENGUE IgM assay, notably at the early stage of DENV infection (first five days post symptom onset), and a strong performance of the VIDAS® Anti-DENGUE IgG assay at later stages of infection, either alone or in combination with the VIDAS® Anti-DENGUE IgM assay. These results therefore further support the use of the three VIDAS® Dengue immunoassays as a complete solution for the rapid, automated and reliable diagnosis of DENV infection in dengue-endemic regions. 488

489

481

460

461

462

Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Index values of the 490 VIDAS<sup>®</sup> dengue assays, in the total population and per DENV infection stage, Figure S2: Extended study flow diagram 491 describing the concordance analysis on common samples shown in Table S5, Table S1: Distribution of samples according 492 to the time from symptom onset, per DENV infection stage, Table S2: Median and interquartile range (IQR) of VIDAS® 493 dengue assays, in the total population and per DENV infection stage (see Figure S1), Table S3: Percentage of positive 494 test results of combined NS1/IgM and IgM/IgG VIDAS® dengue assays vs. single assays, in the acute and post-acute 495 stages of DENV infection, respectively, Table S4: Description of the discordant infection stage classifications between 496 the VIDAS®-based and the competitor ELISA-based algorithm, Table S5: Concordance of the VIDAS® dengue assays 497 with the respective competitor ELISA, in the global population and per stage of DENV infection (common samples; see 498 Figure S2), Table S6: Concordance of the VIDAS® dengue assays with the respective competitor ELISA, according to 499 time intervals post symptom onset. 500

Author Contributions: Conceptualization, M.T., S.D. and M.L.N.; methodology, L.B. and L.D.; software, L.D.; valida-501tion, M.T., S.D. and M.L.N.; formal analysis, L.B.; investigation, A.F.V., A.K., T.M.I.L.S., B.H.G.A.M., A.C., A.C.S. and502F.S.; resources, A.K., C.F.E., A.C., A.C.S. and F.S.; data curation, L.D.; writing—review and editing, M.T., L.B., S.D.,503A.F.V. and M.L.N.; supervision, S.D. and M.L.N.; project administration, M.T. All authors have read and agreed to the504published version of the manuscript.505

Funding: This study was funded by bioMérieux. The APC was funded by bioMérieux.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of507Helsinki, and approved by the respective institutional review boards (Comité d'Éthique pour la Recherche en Santé508[CERS], Ministère de la Santé, Ministère de l'Enseignement Supérieur, de la Recherche Scientifique et de l'Innovation,509Burkina Faso, No. 2020-4-076, dated 8 April 2020; Ethics Committee for Research on Human Beings of the Faculty of510Medicine of São José do Rio Preto, FAMERP, Brazil, No. 4.032.814, dated 18 May 2020 for the prospective collection and511No. 02078812.8.0000.5415, dated 27 May 2019 for the retrospective collection).512

Informed Consent Statement: Written informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available within the article and supplementary material. 515

Acknowledgments: The authors are grateful to Agnès Foussadier (bioMérieux) for her scientific contribution, Françoise 516 Gay-Andrieu (bioMérieux) for her medical advisory support, Nadège Goutagny (bioMérieux) for discussions on the 517 manuscript, Nafissatou Ilboudo, Fatoumata Maïga, Zoumana Bado, Adéline Sandwidi, Félix Lompo and Yacouba Barro 518 (IRSS) for their contribution in patient enrolment and baseline data collection, and to Jacques simpore (CERBA), Théo-519 phane Yonli (CERBA) and Arthur Djibougou (IRSS/Centre MURAZ) for their support in the conduct of the clinical trial. 520 A.F.V. was a postdoctoral fellow of the São Paulo Research Foundation (FAPESP #2018/17647-0) during the time of this 521 research. The authors thank Anne Rascle of AR Medical Writing (Regensburg, Germany) for providing medical writing 522 support, which was funded by bioMérieux (Marcy L'Etoile, France), in accordance with Good Publication Practice 523 (GPP3) guidelines (http://www.ismpp.org/gpp3; accessed 11 February 2022). 524

Conflicts of Interest:L.B., L.D., F.S. and M.T. are employees of bioMérieux.M.L.N. and S.D. received compensation525fees from bioMérieux for this study, in the framework of the agreement signed with their employer entity.526526was funded by bioMérieux.The funder was involved in the design and execution of the study, in data interpretation527and in writing of the manuscript.528

529

506

5	3	1
5	3	2
5	3	3
5	3	4
5	3	5
5	2 2	6
5	2	7
5	2	/ 0
5	3	0
5	3 ⊿	9 0
Э г	4	1
5 -	4	1
5	4	2
5	4	3
5	4	4
5	4	5
5	4	6
5	4	7
5	4	8
5	4	9
5	5	0
5	5	1
5	5	2
5	5	3
5	5	4
5	5	5
5	5	6
5	5	7
5	5	, 8
5	5	g
5	6	ñ
5	6	1
5	6	1 2
5	6	2
5	6	1
Э г	6 6	4
5 -	6	5
5	6	6
5	6	/
5	6	8
5	6	9
5	7	0
5	7	1
5	7	2
5	7	3
5	7	4
5	7	5
5	7	6
5	7	7
5	7	8
5	7	9
5	8	0
5	8	1
5	8	2
5	8	3
-	_	

584

585

586

587

588

530

#### References

- 1. Harapan, H.; Michie, A.; Sasmono, R.T.; Imrie, A. Dengue: A Minireview. *Viruses* **2020**, *12*, 829, doi:10.3390/v12080829.
- 2. Wilder-Smith, A.; Ooi, E.-E.; Horstick, O.; Wills, B. Dengue. Lancet 2019, 393, 350–363, doi:10.1016/S0140-6736(18)32560-1.
- 3. Bhatt, S.; Gething, P.W.; Brady, O.J.; Messina, J.P.; Farlow, A.W.; Moyes, C.L.; Drake, J.M.; Brownstein, J.S.; Hoen, A.G.; Sankoh, O.; et al. The Global Distribution and Burden of Dengue. *Nature* **2013**, *496*, 504–507, doi:10.1038/nature12060.
- 4. Cucunawangsih, null; Lugito, N.P.H. Trends of Dengue Disease Epidemiology. *Virology (Auckl)* **2017**, *8*, 1178122X17695836, doi:10.1177/1178122X17695836.
- 5. *Dengue: Guidelines for Diagnosis, Treatment, Prevention, and Control;* WHO, Ed.; New edition.; World Health Organization (WHO) and the Special Programme for Research and Training in Tropical Diseases (TDR): Geneva, Switzerland, 2009; ISBN 978-92-4-154787-1.
- 6. Raafat, N.; Blacksell, S.D.; Maude, R.J. A Review of Dengue Diagnostics and Implications for Surveillance and Control. *Transactions of The Royal Society of Tropical Medicine and Hygiene* **2019**, *113*, 653–660, doi:10.1093/trstmh/trz068.
- 7. Center for Disease Control and Prevention Testing for Dengue Virus | Dengue | CDC Available online: https://www.cdc.gov/dengue/healthcare-providers/testing/index.html (accessed on 27 October 2021).
- 8. Pan American Health Organization; World Health Organization *Dengue: Guidelines for Patient Care in the Region of the Americas;* 2016; ISBN 978-92-75-31890-4.
- 9. Peeling, R.W.; Artsob, H.; Pelegrino, J.L.; Buchy, P.; Cardosa, M.J.; Devi, S.; Enria, D.A.; Farrar, J.; Gubler, D.J.; Guzman, M.G.; et al. Evaluation of Diagnostic Tests: Dengue. *Nat Rev Microbiol* **2010**, *8*, S30-38, doi:10.1038/nrmicro2459.
- 10. Blacksell, S.D.; Jarman, R.G.; Gibbons, R.V.; Tanganuchitcharnchai, A.; Mammen, M.P.; Nisalak, A.; Kalayanarooj, S.; Bailey, M.S.; Premaratna, R.; de Silva, H.J.; et al. Comparison of Seven Commercial Antigen and Antibody Enzyme-Linked Immunosorbent Assays for Detection of Acute Dengue Infection. *Clin Vaccine Immunol* **2012**, *19*, 804–810, doi:10.1128/CVI.05717-11.
- 11. Blacksell, S.D. Commercial Dengue Rapid Diagnostic Tests for Point-of-Care Application: Recent Evaluations and Future Needs? *J Biomed Biotechnol* **2012**, 2012, 151967, doi:10.1155/2012/151967.
- Blacksell, S.D.; Jarman, R.G.; Bailey, M.S.; Tanganuchitcharnchai, A.; Jenjaroen, K.; Gibbons, R.V.; Paris, D.H.; Premaratna, R.; de Silva, H.J.; Lalloo, D.G.; et al. Evaluation of Six Commercial Point-of-Care Tests for Diagnosis of Acute Dengue Infections: The Need for Combining NS1 Antigen and IgM/IgG Antibody Detection to Achieve Acceptable Levels of Accuracy. *Clin Vaccine Immunol* 2011, *18*, 2095–2101, doi:10.1128/CVI.05285-11.
- 13. Muller, D.A.; Depelsenaire, A.C.I.; Young, P.R. Clinical and Laboratory Diagnosis of Dengue Virus Infection. *J Infect Dis* **2017**, 215, S89–S95, doi:10.1093/infdis/jiw649.
- 14. Fry, S.R.; Meyer, M.; Semple, M.G.; Simmons, C.P.; Sekaran, S.D.; Huang, J.X.; McElnea, C.; Huang, C.-Y.; Valks, A.; Young, P.R.; et al. The Diagnostic Sensitivity of Dengue Rapid Test Assays Is Significantly Enhanced by Using a Combined Antigen and Antibody Testing Approach. *PLoS Negl Trop Dis* **2011**, *5*, e1199, doi:10.1371/journal.pntd.0001199.
- Pal, S.; Dauner, A.L.; Valks, A.; Forshey, B.M.; Long, K.C.; Thaisomboonsuk, B.; Sierra, G.; Picos, V.; Talmage, S.; Morrison, A.C.; et al. Multicountry Prospective Clinical Evaluation of Two Enzyme-Linked Immunosorbent Assays and Two Rapid Diagnostic Tests for Diagnosing Dengue Fever. J Clin Microbiol 2015, 53, 1092–1102, doi:10.1128/JCM.03042-14.
- Blessmann, J.; Winkelmann, Y.; Keoviengkhone, L.; Sopraseuth, V.; Kann, S.; Hansen, J.; El Halas, H.; Emmerich, P.; Schmidt-Chanasit, J.; Schmitz, H.; et al. Assessment of Diagnostic and Analytic Performance of the SD Bioline Dengue Duo Test for Dengue Virus (DENV) Infections in an Endemic Area (Savannakhet Province, Lao People's Democratic Republic). *PLoS One* 2020, *15*, e0230337, doi:10.1371/journal.pone.0230337.
- 17. Simonnet, C.; Okandze, A.; Matheus, S.; Djossou, F.; Nacher, M.; Mahamat, A. Prospective Evaluation of the SD BIOLINE Dengue Duo Rapid Test during a Dengue Virus Epidemic. *Eur J Clin Microbiol Infect Dis* **2017**, *36*, 2441–2447, doi:10.1007/s10096-017-3083-8.
- Hunsperger, E.A.; Yoksan, S.; Buchy, P.; Nguyen, V.C.; Sekaran, S.D.; Enria, D.A.; Pelegrino, J.L.; Vázquez, S.; Artsob, H.; Drebot, M.; et al. Evaluation of Commercially Available Anti-Dengue Virus Immunoglobulin M Tests. *Emerg Infect Dis* 2009, 15, 436–440, doi:10.3201/eid1503.080923.
- 19. Pal, S.; Dauner, A.L.; Mitra, I.; Forshey, B.M.; Garcia, P.; Morrison, A.C.; Halsey, E.S.; Kochel, T.J.; Wu, S.-J.L. Evaluation of Dengue NS1 Antigen Rapid Tests and ELISA Kits Using Clinical Samples. *PLoS One* **2014**, *9*, e113411, doi:10.1371/journal.pone.0113411.
- Gaikwad, S.; Sawant, S.S.; Shastri, J.S. Comparison of Nonstructural Protein-1 Antigen Detection by Rapid and Enzyme-Linked Immunosorbent Assay Test and Its Correlation with Polymerase Chain Reaction for Early Diagnosis of Dengue. *J Lab Physicians* 2017, *9*, 177–181, doi:10.4103/0974-2727.208265.
- Lee, H.; Ryu, J.H.; Park, H.S.; Park, K.H.; Bae, H.; Yun, S.; Choi, A.R.; Cho, S.Y.; Park, C.; Lee, D.G.; et al. Comparison of Six Commercial Diagnostic Tests for the Detection of Dengue Virus Non-Structural-1 Antigen and IgM/IgG Antibodies. *Ann Lab Med* 2019, 39, 566–571, doi:10.3343/alm.2019.39.6.566.
- 22. Hunsperger, E.A.; Yoksan, S.; Buchy, P.; Nguyen, V.C.; Sekaran, S.D.; Enria, D.A.; Vazquez, S.; Cartozian, E.; Pelegrino, J.L.; Artsob, H.; et al. Evaluation of Commercially Available Diagnostic Tests for the Detection of Dengue Virus NS1 Antigen and Anti-Dengue Virus IgM Antibody. *PLoS Negl Trop Dis* **2014**, *8*, e3171, doi:10.1371/journal.pntd.0003171.
- 23. Zhang, H.; Li, W.; Wang, J.; Peng, H.; Che, X.; Chen, X.; Zhou, Y. NS1-Based Tests with Diagnostic Utility for Confirming Dengue Infection: A Meta-Analysis. *Int J Infect Dis* **2014**, *26*, 57–66, doi:10.1016/j.ijid.2014.02.002.

24. Somlor, S.; Brossault, L.; Grandadam, M. Evaluation of VIDAS® Diagnostic Assay Prototypes Detecting Dengue Virus NS1 Antigen and Anti-Dengue Virus IgM and IgG Antibodies. *Diagnostics (Basel)* **2021**, *11*, 1228, doi:10.3390/diagnostics11071228.

589

590

591

592

593

594

595

596

597

598

599 600

601

602

603

604

605 606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626 627

628

629

630

631 632

633

634

635

636 637

638

639

640

641

642

643

644 645

- 25. Colombo, T.E.; Versiani, A.F.; Dutra, K.R.; Rubiato, J.G.D.; Galvão, T.M.; Negri Reis, A.F.; Nogueira, M.L. Performance of CDC Trioplex QPCR during a Dengue Outbreak in Brazil. *J Clin Virol* **2019**, *121*, 104208, doi:10.1016/j.jcv.2019.104208.
- 26. Johnson, B.W.; Russell, B.J.; Lanciotti, R.S. Serotype-Specific Detection of Dengue Viruses in a Fourplex Real-Time Reverse Transcriptase PCR Assay. *J Clin Microbiol* **2005**, *43*, 4977–4983, doi:10.1128/JCM.43.10.4977-4983.2005.
- 27. Combe, M.; Lacoux, X.; Martinez, J.; Méjan, O.; Luciani, F.; Daniel, S. Expression, Refolding and Bio-Structural Analysis of a Tetravalent Recombinant Dengue Envelope Domain III Protein for Serological Diagnosis. *Protein Expr Purif* **2017**, *133*, 57–65, doi:10.1016/j.pep.2017.03.004.
- 28. Clinical & Laboratory Standards Institute EP05-A3: Evaluating Quantitative Measurement Precision, 3rd Edition Available online: https://clsi.org/standards/products/method-evaluation/documents/ep05/ (accessed on 27 October 2021).
- 29. Clinical & Laboratory Standards Institute EP07: Interference Testing in Clinical Chemistry Third Edition Available online: https://clsi.org/standards/products/method-evaluation/documents/ep07/ (accessed on 26 January 2022).
- 30. Clinical & Laboratory Standards Institute EP12-A2: User Protocol for Evaluation of Qualitative Test Performance, 2nd Edition Available online: https://clsi.org/standards/products/method-evaluation/documents/ep12/ (accessed on 12 October 2022).
- 31. Ambrose, J.H.; Sekaran, S.D.; Azizan, A. Dengue Virus NS1 Protein as a Diagnostic Marker: Commercially Available ELISA and Comparison to QRT-PCR and Serological Diagnostic Assays Currently Used by the State of Florida. *J Trop Med* **2017**, 2017, 8072491, doi:10.1155/2017/8072491.
- 32. Tate, J.; Ward, G. Interferences in Immunoassay. Clin Biochem Rev 2004, 25, 105–120.
- 33. Piantadosi, A.; Kanjilal, S. Diagnostic Approach for Arboviral Infections in the United States. *J Clin Microbiol* **2020**, *58*, e01926-19, doi:10.1128/JCM.01926-19.
- 34. Endale, A.; Medhin, G.; Darfiro, K.; Kebede, N.; Legesse, M. Magnitude of Antibody Cross-Reactivity in Medically Important Mosquito-Borne Flaviviruses: A Systematic Review. *Infect Drug Resist* **2021**, *14*, 4291–4299, doi:10.2147/IDR.S336351.
- 35. Souza, N.C.S.E.; Félix, A.C.; de Paula, A.V.; Levi, J.E.; Pannuti, C.S.; Romano, C.M. Evaluation of Serological Cross-Reactivity between Yellow Fever and Other Flaviviruses. *Int J Infect Dis* **2019**, *81*, 4–5, doi:10.1016/j.ijid.2019.01.023.
- 36. Koraka, P.; Zeller, H.; Niedrig, M.; Osterhaus, A.D.M.E.; Groen, J. Reactivity of Serum Samples from Patients with a Flavivirus Infection Measured by Immunofluorescence Assay and ELISA. *Microbes Infect* **2002**, *4*, 1209–1215, doi:10.1016/s1286-4579(02)01647-7.
- 37. Lustig, Y.; Keler, S.; Kolodny, R.; Ben-Tal, N.; Atias-Varon, D.; Shlush, E.; Gerlic, M.; Munitz, A.; Doolman, R.; Asraf, K.; et al. Potential Antigenic Cross-Reactivity between SARS-CoV-2 and Dengue Viruses. *Clinical Infectious Diseases* **2020**, ciaa1207, doi:10.1093/cid/ciaa1207.
- 38. Nath, H.; Mallick, A.; Roy, S.; Sukla, S.; Biswas, S. Computational Modelling Supports That Dengue Virus Envelope Antibodies Can Bind to SARS-CoV-2 Receptor Binding Sites: Is Pre-Exposure to Dengue Virus Protective against COVID-19 Severity? *Comput Struct Biotechnol J* **2021**, *19*, 459–466, doi:10.1016/j.csbj.2020.12.037.
- 39. Spinicci, M.; Bartoloni, A.; Mantella, A.; Zammarchi, L.; Rossolini, G.M.; Antonelli, A. Low Risk of Serological Cross-Reactivity between Dengue and COVID-19. *Mem Inst Oswaldo Cruz* **2020**, *115*, e200225, doi:10.1590/0074-02760200225.
- 40. Nath, H.; Mallick, A.; Roy, S.; Sukla, S.; Basu, K.; De, A.; Biswas, S. Archived Dengue Serum Samples Produced False-Positive Results in SARS-CoV-2 Lateral Flow-Based Rapid Antibody Tests. *J Med Microbiol* **2021**, *70*, doi:10.1099/jmm.0.001369.
- 41. Vanroye, F.; Bossche, D.V. den; Brosius, I.; Tack, B.; Esbroeck, M.V.; Jacobs, J. COVID-19 Antibody Detecting Rapid Diagnostic Tests Show High Cross-Reactivity When Challenged with Pre-Pandemic Malaria, Schistosomiasis and Dengue Samples. *Diagnostics (Basel)* **2021**, *11*, 1163, doi:10.3390/diagnostics11071163.
- 42. Masyeni, S.; Santoso, M.S.; Widyaningsih, P.D.; Asmara, D.W.; Nainu, F.; Harapan, H.; Sasmono, R.T. Serological Cross-Reaction and Coinfection of Dengue and COVID-19 in Asia: Experience from Indonesia. *Int J Infect Dis* **2021**, *102*, 152–154, doi:10.1016/j.ijid.2020.10.043.
- 43. Santoso, M.S.; Masyeni, S.; Haryanto, S.; Yohan, B.; Hibberd, M.L.; Sasmono, R.T. Assessment of Dengue and COVID-19 Antibody Rapid Diagnostic Tests Cross-Reactivity in Indonesia. *Virol J* **2021**, *18*, 54, doi:10.1186/s12985-021-01522-2.
- 44. Khairunisa, S.Q.; Amarullah, I.H.; Churrotin, S.; Fitria, A.L.; Amin, M.; Lusida, M.I.; Soegijanto, S. Potential Misdiagnosis between COVID-19 and Dengue Infection Using Rapid Serological Test. *Infect Dis Rep* **2021**, *13*, 540–551, doi:10.3390/idr13020050.
- 45. Harapan, H.; Ryan, M.; Yohan, B.; Abidin, R.S.; Nainu, F.; Rakib, A.; Jahan, I.; Emran, T.B.; Ullah, I.; Panta, K.; et al. Covid-19 and Dengue: Double Punches for Dengue-Endemic Countries in Asia. *Rev Med Virol* **2021**, *31*, e2161, doi:10.1002/rmv.2161.
- 46. Schulte, H.L.; Brito-Sousa, J.D.; Lacerda, M.V.G.; Naves, L.A.; de Gois, E.T.; Fernandes, M.S.; Lima, V.P.; Rassi, C.H.R.E.; de Siracusa, C.C.; Sasaki, L.M.P.; et al. SARS-CoV-2/DENV Co-Infection: A Series of Cases from the Federal District, Midwestern Brazil. *BMC Infect Dis* **2021**, *21*, 727, doi:10.1186/s12879-021-06456-2.
- Mejía-Parra, J.L.; Aguilar-Martinez, S.; Fernández-Mogollón, J.L.; Luna, C.; Bonilla-Aldana, D.K.; Rodriguez-Morales, A.J.; Díaz-Vélez, C. Characteristics of Patients Coinfected with Severe Acute Respiratory Syndrome Coronavirus 2 and Dengue Virus, Lambayeque, Peru, May-August 2020: A Retrospective Analysis. *Travel Med Infect Dis* 2021, 43, 102132, doi:10.1016/j.tmaid.2021.102132.
- Messina, J.P.; Brady, O.J.; Scott, T.W.; Zou, C.; Pigott, D.M.; Duda, K.A.; Bhatt, S.; Katzelnick, L.; Howes, R.E.; Battle, K.E.; et al. Global Spread of Dengue Virus Types: Mapping the 70 Year History. *Trends Microbiol* 2014, 22, 138–146, 647 doi:10.1016/j.tim.2013.12.011.



**Figure S1.** Index values of the VIDAS<sup>®</sup> dengue assays, in the total population and per DENV infection stage. VIDAS<sup>®</sup> Dengue NS1 Antigen (**a**), IgM (**b**) and IgG (**c**) assays were performed as described in the Methods section. Index values are depicted as Tukey boxplots in the whole study population (Total) and according to the DENV infection stages (Acute, Acute within 0 to 5 days post symptom onset [D0-5], Post-Acute, Recovery, Naïve and Unclassified), as defined in Table 3. The grey dashed line indicates the positivity cutoff (i = 1.0). The number of samples (N) per group is shown above each box. Respective median (interquartile range) index values are shown in Table S2.



Figure S2. Extended study flow diagram describing the concordance analysis on common samples shown in Table S5.

Days from	Stage of DENV infection <sup>1</sup> , N (%)									
symptom onset	Acute	Post-Acute	Recovery	Naïve	Unclassified	Total				
0 – 3 days	102 (36.3%)	6 (4.9%)	258 (41.2%)	88 (50.3%)	23 (25.3%)	477				
4 – 5 days	61 (21.7%)	7 (5.7%)	119 (19.0%)	24 (13.7%)	17 (18.7%)	228				
6 – 8 days	95 (33.8%)	101 (82.1%)	169 (27.0%)	48 (27.4%)	43 (47.2%)	456				
9 – 15 days	11 (3.9%)	8 (6.5%)	43 (6.9%)	12 (6.9%)	4 (4.4%)	78				
16 days – 1 month	7 (2.5%)	0 (0.0%)	23 (3.7%)	2 (1.1%)	2 (2.2%)	34				
>1 month	1 (0.4%)	0 (0.0%)	12 (1.9%)	1 (0.6%)	2 (2.2%)	16				
Unknown	4 (1.4%)	1 (0.8%)	2 (0.3%)	0 (0.0%)	0 (0.0%)	7				
Total	281	123	626	175	91	1296				

Table S1. Distribution of samples according to the time from symptom onset, per DENV infection stage.

<sup>1</sup> As defined in Table 3.

VIDAS®		DENV infection stage						
dengue assay	variable	Total	Acute	Acute D0-5	Post-Acute	Recovery	Naïve	Unclassified
	Ν	1296	281	163	123	626	175	91
NS1	Median	0.2	2.8	10.5	0.2	0.1	0.1	0.1
-	IQR	0.1-0.3	0.4-54.1	1.6-81.1	0.1-0.3	0.1-0.2	0.1-0.2	0.1-0.2
IgM	Ν	1296	281	163	123	626	175	91
	Median	0.6	2.1	4.7	2.5	0.4	0.4	0.6
	IQR	0.3-2.0	0.6-8.9	0.6-18.0	1.0-7.6	0.2-0.9	0.2-0.6	0.3-1.7
	Ν	1296	281	163	123	626	175	91
IgG	Median	6.7	6.2	10.7	53.0	8.2	0.4	19.6
	IQR	1.0-19.2	0.7-25.3	2.2-29.7	1.4-65.3	3.4-15.1	0.2-0.6	4.6-41.5

**Table S2.** Median and interquartile range (IQR) of VIDAS<sup>®</sup> dengue assays, in the total population and per DENV infection stage (see Figure S1).

Denvilation		% positive test results		
Population	VIDAS <sup>®</sup> dengue assay	$n/N^{1}$	% [95% CI]	
	NS1	194/281	69.0% [63.4-74.2]	
Acute (all)	IgM	175/281	62.3% [56.5-67.7]	
	NS1/IgM <sup>2</sup>	233/281	82.9% [78.1-86.9]	
	NS1	131/163	80.4% [73.6-85.7]	
Acute (D0-5)	IgM	108/163	66.3% [58.7-73.1]	
	NS1/IgM <sup>2</sup>	141/163	86.5% [80.4-90.9]	
	IgM	92/123	74.8% [66.5-81.6]	
Post-Acute	IgG	99/123	80.5% [72.6-86.5]	
	IgM/IgG <sup>3</sup>	113/123	91.9% [85.7-95.5]	

**Table S3.** Percentage of positive test results of combined NS1/IgM and IgM/IgG VIDAS<sup>®</sup> dengue assays *vs.* single assays, in the acute and post-acute stages of DENV infection, respectively.

 $^{1}$  *n*/*N* is the ratio of the number of samples positive with the respective VIDAS<sup>®</sup> Dengue assays to the total number of samples in the indicated DENV infection stage. <sup>2</sup>Percentage of tests positive for VIDAS<sup>®</sup> NS1 and/or IgM; <sup>3</sup> Percentage of tests positive for VIDAS<sup>®</sup> IgM and/or IgG. Abbreviations: CI, confidence interval; D0-5, 0-5 days post symptom-onset.

Table S4. Description of the discordant infection stage classifications between the VIDAS<sup>®</sup>-based and the competitor ELISA-based algorithm

Stage of DENV	Disagreement	VIDAS <sup>®</sup> -based classification ( <i>n</i> ) <sup>2</sup>						
infection <sup>3</sup>	n/N 1 (%)	Acute	Post-Acute	Recovery	Naïve	Unclassified		
Acute (all)	32/281 (11.4%)	-	18	4	3	7		
Acute (D0-5)	7/163 (4.3%)	-	5	1	0	1		
Post-Acute	45/123 (36.6%)	0	-	21	10	14		
Recovery	196/626 (31.3%)	5	132	-	46	13		
Naïve	33/175 (18.9%)	0	9	10	-	14		
Unclassified	89/91 (97.8%)	1	31	50	7	-		

 $^{1}$  *n*/*N* is the ratio of the number of samples whose classification using the defined rules (Table 3) by the VIDAS<sup>®</sup> assays was discordant with that by the competitor ELISA, to the number of samples classified by the competitor ELISA-based algorithm;  $^{2}$  *n* is the number of discordant samples per stage (according to VIDAS<sup>®</sup>-based classification). <sup>3</sup> According to the RT-PCR- and competitor ELISA-based algorithm (Table 3).

VIDAS®		Posi	tive Agreement	Neg	ative Agreement	Overall Agreement	
dengue assay	Population	$n/N^{1}$	% [95% CI]	$n/N^{1}$	% [95% CI]	$n/N^{1}$	% [95% CI]
	Total	135/170	79.4% [72.7-84.8]	963/968	99.5% [98.8-99.8]	1098/1138	96.5% [95.2-97.5]
_	Acute (all)	135/170	79.4% [72.7-84.8]	43/43	100.0% [91.8-100.0]	178/213	83.6% [78.0-87.9]
NS1	Acute (D0-5)	89/98	90.8% [83.5-95.1]	20/20	100.0% [83.2-100.0]	109/118	92.4% [86.1-95.9]
-	Post-Acute	N/A	-	123/123	100.0% [97.0-100.0]	N/A	-
	Recovery	N/A	-	621/626	99.2% [98.1-99.7]	N/A	-
-	Total	213/266	80.1% [74.9-84.4]	686/872	78.7% [75.8-81.3]	899/1138	79.0% [76.5-81.3]
	Acute (all)	120/142	84.5% [77.7-89.5]	57/71	80.3% [69.6-87.9]	177/213	83.1% [77.5-87.5]
IgM	Acute (D0-5)	65/74	87.8% [78.5-93.5]	34/44	77.3% [63.0-87.2]	99/118	83.9% [76.2-89.4]
-	Post-Acute	92/123	74.8% [66.5-81.6]	N/A	-	N/A	-
-	Recovery	N/A	-	477/626	76.2% [72.7-79.4]	N/A	-
	Total	811/948	85.5% [83.2-87.6]	164/190	86.3% [80.7-90.5]	975/1138	85.7% [83.5-87.6]
-	Acute (all)	145/199	72.9% [66.3-78.6]	8/14	57.1% [32.6-78.6]	153/213	71.8% [65.4-77.4]
IgG _	Acute (D0-5)	91/110	82.7% [74.6-88.7]	2/8	25.0% [7.1-59.1]	93/118	78.8% [70.6-85.2]
	Post-Acute	99/123	80.5% [72.6-86.5]	N/A	-	N/A	-
	Recovery	567/626	90.6% [88.0-92.6]	N/A	-	N/A	-

Table S5. Concordance of the VIDAS<sup>®</sup> dengue assays with the respective competitor ELISA, in the global population and per stage of DENV infection (common samples; see Figure S2)

 $^{1}$  *n*/*N* is the ratio of the number of samples for which VIDAS<sup>®</sup> assays are in agreement (positive, negative and overall) with the competitor ELISA (reference test) to the number of samples tested either positive or negative (and overall) with the competitor ELISA. Abbreviations: CI, confidence interval; D0-5, 0-5 days post symptom-onset; N/A, not applicable.

		Positive Percent Agreement		Nega	tive Percent Agreement	Ove	Overall Percent Agreement	
VIDAS® dengue assay	Time interval post symptom onset	$n/N^{1}$	% [95% CI]	<b>n/N</b> <sup>1</sup>	% [95% CI]	<i>n/N</i> <sup>1</sup>	% [95% CI]	
	0 – 3 days	79 / 84	94.05% [ 86.81 ; 97.43 ] %	388 / 392	98.98% [ 97.41 ; 99.72 ] %	467 / 476	98.11% [ 96.44 ; 99.13 ] %	
	4 – 5 days	49 / 54	90.74% [ 80.09 ; 95.98 ] %	172 / 174	98.85% [ 95.91 ; 99.86 ] %	221 / 228	96.93% [ 93.78 ; 98.76 ] %	
	6 – 8 days	55 / 77	71.43% [ 60.51 ; 80.31 ] %	377 / 379	99.47% [ 98.11 ; 99.94 ] %	432 / 456	94.74% [ 92.29 ; 96.44 ] %	
NS1	9 – 15 days	4 / 7	57.14% [ 25.05 ; 84.18 ] %	71 / 71	100.00% [ 94.94 ; 100.00 ] %	75 / 78	96.15% [ 89.17 ; 99.20 ] %	
	16 days – 1 month	0/3	0.00% [ 0.00 ; 70.76 ] %	31 / 31	100.00% [ 88.78 ; 100.00 ] %	31 / 34	91.18% [ 77.04 ; 96.95 ] %	
	>1 month	0 / 0	. [ 0.00 ; 0.00 ] %	16 / 16	100.00% [ 79.41 ; 100.00 ] %	16 / 16	100.00% [ 79.41 ; 100.00 ] %	
	Unknown	4 / 4	100.00% [ 39.76 ; 100.00 ] %	3/3	100.00% [ 29.24 ; 100.00 ] %	7/7	100.00% [ 59.04 ; 100.00 ] %	
	0 – 3 days	39 / 46	84.78% [ 71.78 ; 92.43 ] %	300 / 380	78.95% [ 74.57 ; 82.75 ] %	339 / 426	79.58% [ 75.49 ; 83.13 ] %	
	4 – 5 days	37 / 41	90.24% [ 77.45 ; 96.14 ] %	110 / 157	70.06% [ 62.49 ; 76.68 ] %	147 / 198	74.24% [ 67.73 ; 79.83 ] %	
	6 – 8 days	126 / 164	76.83% [ 69.80 ; 82.63 ] %	193 / 233	82.83% [ 77.47 ; 87.13 ] %	319 / 397	80.35% [ 76.16 ; 83.96 ] %	
Igivi	9 – 15 days	9 / 11	81.82% [ 52.30 ; 94.86 ] %	49 / 60	81.67% [ 70.08 ; 89.44 ] %	58 / 71	81.69% [ 71.15 ; 88.98 ] %	
	16 days – 1 month	0 / 0	. [ 0.00 ; 0.00 ] %	25 / 31	80.65% [ 63.72 ; 90.81 ] %	25 / 31	80.65% [ 63.72 ; 90.81 ] %	
	>1 month	1/1	100.00% [ 2.50 ; 100.00 ] %	10 / 13	76.92% [ 49.74 ; 91.82 ] %	11 / 14	78.57% [ 52.41 ; 92.43 ] %	
	Unknown	1/3	33.33% [ 6.15 ; 79.23 ] %	2 / 2	100.00% [ 15.81 ; 100.00 ] %	3 / 5	60.00% [ 23.07 ; 88.24 ] %	
	0 – 3 days	344 / 380	90.53% [ 87.16 ; 93.08 ] %	81 / 95	85.26% [ 76.77 ; 91.01 ] %	425 / 475	89.47% [ 86.39 ; 91.92 ] %	
	4 – 5 days	174 / 200	87.00% [ 81.63 ; 90.97 ] %	22 / 27	81.48% [ 63.30 ; 91.82 ] %	196 / 227	86.34% [ 81.27 ; 90.21 ] %	
	6 – 8 days	326 / 400	81.50% [ 77.40 ; 85.00 ] %	52 / 56	92.86% [ 83.02 ; 97.19 ] %	378 / 456	82.89% [ 79.17 ; 86.07 ] %	
IgG	9 – 15 days	52 / 66	78.79% [ 67.49 ; 86.92 ] %	9 / 12	75.00% [ 46.77 ; 91.11 ] %	61 / 78	78.21% [ 67.84 ; 85.92 ] %	
	16 days – 1 month	27 / 30	90.00% [ 74.38 ; 96.54 ] %	4 / 4	100.00% [ 39.76 ; 100.00 ] %	31 / 34	91.18% [ 77.04 ; 96.95 ] %	
	>1 month	11 / 14	78.57% [ 52.41 ; 92.43 ] %	2/2	100.00% [ 15.81 ; 100.00 ] %	13 / 16	81.25% [ 56.99 ; 93.41 ] %	
	Unknown	6/6	100.00% [ 54.07 ; 100.00 ] %	0 / 1	0.00% [ 0.00 ; 97.50 ] %	6/7	85.71% [ 48.69 ; 97.43 ] %	

Table S6. Concordance of the VIDAS<sup>®</sup> dengue assays with the respective competitor ELISA, according to time intervals post symptom onset.

 $^{1}$  n/N is the ratio of the number of samples for which VIDAS<sup>®</sup> assays are in agreement (positive, negative and overall) with the competitor ELISA (reference test) to the number of samples tested either positive or negative (and overall) with the competitor ELISA. Abbreviation: CI, confidence interval